Associations of psychiatric disease and aging on FKBP5 expression converge on cortical supragranular neurons

Identification and characterisation of novel targets for treatment is a priority in the field of psychiatry. FKBP5 is a gene with decades of evidence suggesting its pathogenic role in a subset of psychiatric patients, with potential to be leveraged as a therapeutic target for these individuals. While it is widely reported that FKBP5/FKBP51 mRNA/protein (FKBP5/1) expression is impacted by psychiatric disease state, risk genotype and age, it is not known in which cell-types and sub-anatomical areas of the human brain this occurs. This knowledge is critical to propel FKBP5/1-targeted treatment development. Here, we performed an extensive, large-scale postmortem study (n=1024) of FKBP5/1 examining prefrontal cortex (BA9, BA11, BA24) derived from subjects that lived with schizophrenia, major depression or bipolar disorder. With an extensive battery of RNA (bulk RNA sequencing, single-nucleus RNA sequencing, microarray, qPCR, RNAscope) and protein (immunoblot, immunohistochemistry) analysis approaches, we thoroughly investigated the effects of disease-state, aging and genotype on cortical FKBP5/1 expression including in a cell-type specific manner. We identified consistently heightened FKBP5/1 levels in psychopathology and with age, but not genotype, with these effects strongest in schizophrenia. Using single-nucleus RNA sequencing (snRNAseq) and targeted histology, we established that these disease- and aging-effects on FKBP5/1 expression were most pronounced in excitatory supragranular neurons. We then found that this increase in FKBP5 levels likely impacts on synaptic plasticity, as FKBP5 gex levels strongly and inversely correlated with dendritic mushroom spine density and brain-derived neurotrophic factor (BDNF) levels in supragranular neurons. These findings pinpoint a novel cellular and molecular mechanism that has significant potential to open a new avenue of FKBP51 drug development to treat cognitive symptoms in psychiatric disorders.

[1]  Nikola Habek,et al.  Upper cortical layer–driven network impairment in schizophrenia , 2022, Science advances.

[2]  B. Kuster,et al.  Stress-primed secretory autophagy promotes extracellular BDNF maturation by enhancing MMP9 secretion , 2021, Nature Communications.

[3]  M. Thase,et al.  Treatment resistance in psychiatry: state of the art and new directions , 2021, Molecular Psychiatry.

[4]  J. Phillip,et al.  Use of the p-values as a size-dependent function to address practical differences when analyzing large datasets , 2019, Scientific Reports.

[5]  S. Schwab,et al.  How stress physically re-shapes the brain: Impact on brain cell shapes, numbers and connections in psychiatric disorders , 2021, Neuroscience & Biobehavioral Reviews.

[6]  T. Valiante,et al.  Diversity amongst human cortical pyramidal neurons revealed via their sag currents and frequency preferences , 2019, Nature Communications.

[7]  E. Binder,et al.  Severe childhood and adulthood stress associates with neocortical layer-specific reductions of mature spines in psychiatric disorders , 2020, Neurobiology of Stress.

[8]  M. Korte,et al.  BDNF signaling during the lifetime of dendritic spines , 2020, Cell and Tissue Research.

[9]  J. Ragoussis,et al.  Single-nucleus transcriptomics of the prefrontal cortex in major depressive disorder implicates oligodendrocyte precursor cells and excitatory neurons , 2020, Nature Neuroscience.

[10]  H. Akil,et al.  Revisiting the Stress Concept: Implications for Affective Disorders , 2020, The Journal of Neuroscience.

[11]  C. Pariante,et al.  Glucocorticoid exposure during hippocampal neurogenesis primes future stress response by inducing changes in DNA methylation , 2019, Psychoneuroendocrinology.

[12]  E. Binder,et al.  Identification of dynamic glucocorticoid-induced methylation changes at the FKBP5 locus , 2019, Clinical Epigenetics.

[13]  C. Gieger,et al.  Epigenetic upregulation of FKBP5 by aging and stress contributes to NF-κB–driven inflammation and cardiovascular risk , 2019, Proceedings of the National Academy of Sciences.

[14]  Maximilian Haeussler,et al.  Single-cell genomics identifies cell type–specific molecular changes in autism , 2019, Science.

[15]  Longyu Dou,et al.  Loss of FKBP5 Affects Neuron Synaptic Plasticity: An Electrophysiology Insight , 2019, Neuroscience.

[16]  E. Weeber,et al.  The Disease-Associated Chaperone FKBP51 Impairs Cognitive Function by Accelerating AMPA Receptor Recycling , 2019, eNeuro.

[17]  T M Hyde,et al.  GAD1 alternative transcripts and DNA methylation in human prefrontal cortex and hippocampus in brain development, schizophrenia , 2018, Molecular Psychiatry.

[18]  Elisabeth B. Binder,et al.  Understanding the Molecular Mechanisms Underpinning Gene by Environment Interactions in Psychiatric Disorders: The FKBP5 Model , 2018, Biological Psychiatry.

[19]  P. Kharchenko,et al.  Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain , 2017, Nature Biotechnology.

[20]  B. Dean,et al.  Changed gene expression in subjects with schizophrenia and low cortical muscarinic M1 receptors predicts disrupted upstream pathways interacting with that receptor , 2016, Molecular Psychiatry.

[21]  Aviv Regev,et al.  Massively-parallel single nucleus RNA-seq with DroNc-seq , 2017, Nature Methods.

[22]  P. Visscher,et al.  10 Years of GWAS Discovery: Biology, Function, and Translation. , 2017, American journal of human genetics.

[23]  G. Chrousos,et al.  Life stress, glucocorticoid signaling, and the aging epigenome: Implications for aging-related diseases , 2017, Neuroscience & Biobehavioral Reviews.

[24]  Amit Etkin,et al.  Transdiagnostic impairment of cognitive control in mental illness. , 2016, Journal of psychiatric research.

[25]  E. Binder,et al.  Gene–Stress–Epigenetic Regulation of FKBP5: Clinical and Translational Implications , 2016, Neuropsychopharmacology.

[26]  G. Chrousos,et al.  Chaperoning epigenetics: FKBP51 decreases the activity of DNMT1 and mediates epigenetic effects of the antidepressant paroxetine , 2015, Science Signaling.

[27]  L. Selemon,et al.  BA11 FKBP5 expression levels correlate with dendritic spine density in postmortem PTSD and controls , 2015, Neurobiology of Stress.

[28]  R. Sweet,et al.  Dendritic spine alterations in schizophrenia , 2015, Neuroscience Letters.

[29]  F. Holsboer,et al.  Pharmacological Inhibition of the Psychiatric Risk Factor FKBP51 Has Anxiolytic Properties , 2015, The Journal of Neuroscience.

[30]  Elisabeth B. Binder,et al.  Epigenetics of Stress-Related Psychiatric Disorders and Gene × Environment Interactions , 2015, Neuron.

[31]  J. Andrews,et al.  Alterations of mGluR5 and its endogenous regulators Norbin, Tamalin and Preso1 in schizophrenia: towards a model of mGluR5 dysregulation , 2015, Acta Neuropathologica.

[32]  A. Bracher,et al.  Selective inhibitors of the FK506-binding protein 51 by induced fit. , 2015, Nature chemical biology.

[33]  E. Binder,et al.  FKBP5 Allele-Specific Epigenetic Modification in Gene by Environment Interaction , 2015, Neuropsychopharmacology.

[34]  F. McMahon.  Prediction of treatment outcomes in psychiatry—where do we stand ? , 2014, Dialogues in clinical neuroscience.

[35]  Gustavo Deco,et al.  Cortico-cortical communication dynamics , 2014, Front. Syst. Neurosci..

[36]  M. Bennett,et al.  Stress and trauma: BDNF control of dendritic-spine formation and regression , 2014, Progress in Neurobiology.

[37]  E. Binder,et al.  Gene–environment interactions at the FKBP5 locus: sensitive periods, mechanisms and pleiotropism , 2014, Genes, brain, and behavior.

[38]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[39]  C. Hoogenraad,et al.  Shape-induced asymmetric diffusion in dendritic spines allows efficient synaptic AMPA receptor trapping. , 2013, Biophysical journal.

[40]  C. Cotman,et al.  Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. , 2013, The Journal of clinical investigation.

[41]  E. Binder,et al.  Allele-specific epigenetic modification: a molecular mechanism for gene-environment interactions in stress-related psychiatric disorders? , 2013, Epigenomics.

[42]  F. Holsboer,et al.  Genetic variation in FKBP5 associated with the extent of stress hormone dysregulation in major depression , 2013, Genes, brain, and behavior.

[43]  B. Bradley,et al.  Allele-specific FKBP5 DNA demethylation mediates gene–childhood trauma interactions , 2012, Nature Neuroscience.

[44]  D. Lewis,et al.  Electrophysiological classes of layer 2/3 pyramidal cells in monkey prefrontal cortex. , 2012, Journal of neurophysiology.

[45]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[46]  P. Penzes,et al.  Dendritic spine pathology in neuropsychiatric disorders , 2011, Nature Neuroscience.

[47]  E. Binder,et al.  Expression and Regulation of the Fkbp5 Gene in the Adult Mouse Brain , 2011, PloS one.

[48]  David R. Williams,et al.  Childhood adversities and adult psychopathology in the WHO World Mental Health Surveys , 2010, British Journal of Psychiatry.

[49]  G. Chrousos,et al.  The human glucocorticoid receptor: Molecular basis of biologic function , 2010, Steroids.

[50]  A. Arnsten.  Stress signalling pathways that impair prefrontal cortex structure and function , 2009, Nature Reviews Neuroscience.

[51]  C. Economo,et al.  Atlas of Cytoarchitectonics of the Adult Human Cerebral Cortex , 2008 .

[52]  T. Hashimoto,et al.  Molecular mechanisms contributing to dendritic spine alterations in the prefrontal cortex of subjects with schizophrenia , 2006, Molecular Psychiatry.

[53]  David A Lewis,et al.  Intrinsic excitatory connections in the prefrontal cortex and the pathophysiology of schizophrenia , 2000, Brain Research Bulletin.

[54]  L. C. Katz,et al.  Destabilization of Cortical Dendrites and Spines by BDNF , 1999, Neuron.

[55]  L. Garey.  Brodmann's localisation in the cerebral cortex , 1999 .

[56]  B. McEwen,et al.  Stress and cognitive function , 1995, Current Opinion in Neurobiology.

[57]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .